Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial

Pfizer reported seven-year follow-up data from the Phase 3 CROWN trial showing LORBRENA significantly improved progression-free survival versus XALKORI in previously untreated ALK-positive advanced or metastatic non-small cell lung cancer. The update reinforces the drug's clinical profile and supports Pfizer's oncology portfolio. The news is positive for the company, though it is a trial-update release rather than a near-term earnings catalyst.

Analysis

Pfizer reported seven-year follow-up data from the Phase 3 CROWN trial showing LORBRENA significantly improved progression-free survival versus XALKORI in previously untreated ALK-positive advanced or metastatic non-small cell lung cancer. The update reinforces the drug's clinical profile and supports Pfizer's oncology portfolio. The news is positive for the company, though it is a trial-update release rather than a near-term earnings catalyst.